Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000991337 | SCV000515358 | likely benign | not provided | 2021-04-09 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000991337 | SCV000614704 | likely benign | not provided | 2018-12-03 | criteria provided, single submitter | clinical testing | |
Wong Mito Lab, |
RCV000758500 | SCV000887217 | benign | Progressive sclerosing poliodystrophy | 2018-10-01 | criteria provided, single submitter | clinical testing | The NM_002693.2:c.150G>A (NP_002684.1:p.Gln50=) [GRCH38: NC_000015.10:g.89333605C>T] variant in POLG gene is interpretated to be a Benign based on ACMG guidelines (PMID: 25741868). This variant meets the following evidence codes reported in the ACMG-guideline. BS1:The minor allele frequency of this allele is high for Mitochondrial DNA depletion syndrome 4A (Alpers type). BS2:Observation of the variant in controls is inconsistent with penetrance of Mitochondrial DNA depletion syndrome 4A (Alpers type). BP4:Computational evidence/predictors indicate no impact on the POLG structure, function, or protein-protein interaction. BP7:The variant is silent with non predicted splice impact. Based on the evidence criteria codes applied, the variant is suggested to be Benign. |
Labcorp Genetics |
RCV000758500 | SCV001603781 | likely benign | Progressive sclerosing poliodystrophy | 2023-09-21 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002392961 | SCV002705000 | likely benign | Inborn genetic diseases | 2018-08-24 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |